[Form 4] DEXCOM INC Insider Trading Activity

Rhea-AI Filing Summary

Dexcom Inc. President, CEO, and Director Jacob Steven Leach received a grant of 104,516 restricted stock units (RSUs) on March 8, 2026. These RSUs vest in three equal annual installments from the grant date, with each RSU representing a right to one share of common stock.

On the same date, 19,757 shares of common stock at $68.10 per share were withheld to cover tax obligations related to RSU net settlement, which the company notes does not represent a market sale. After these transactions, Leach directly holds 421,810 shares of common stock, including 148,536 unvested RSUs spread across multiple grant years.

In addition, 47,296 shares are held indirectly through the Gregg Family Grandchildren's Trust UAD 12/30/2010, where Leach’s spouse serves as trustee.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leach Jacob Steven

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO, and Director

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/08/2026		A		104,516(1)	A	$0	441,567	D
Common Stock	03/08/2026		F		19,757(2)	D	$68.1	421,810(3)	D
Common Stock								47,296	I	Family Holdings(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.

2. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person.

3. Included in this number are 148,536 unvested RSUs, 104,516 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

4. Shares are held by the Gregg Family Grandchildren's Trust UAD 12/30/2010, with respect to which the Reporting Person's spouse is a trustee.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Jacob Steven Leach	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dexcom (DXCM) CEO Jacob Leach acquire in this Form 4?

Jacob Leach received a grant of 104,516 restricted stock units (RSUs) on March 8, 2026. Each RSU represents a contingent right to one Dexcom common share, vesting in three equal annual installments from the grant date.

Why were 19,757 Dexcom (DXCM) shares disposed of in this filing?

The 19,757 Dexcom shares shown as a disposition were withheld for tax obligations at $68.10 per share. The company explains this withholding relates to RSU net settlement and does not represent an open-market sale by Jacob Leach.

How many Dexcom (DXCM) shares does Jacob Leach hold after these transactions?

Following these transactions, Jacob Leach directly holds 421,810 Dexcom common shares. This direct position includes 148,536 unvested RSUs from grants made in 2024, 2025, and 2026 with scheduled vesting through March 8, 2029.

What unvested RSUs are included in Jacob Leach’s Dexcom (DXCM) holdings?

Leach’s direct holdings include 148,536 unvested RSUs: 104,516 granted March 8, 2026 vesting through March 8, 2029, 23,937 and 11,399 from March 8, 2025 vesting through 2028 and 2027, and 8,684 from March 8, 2024 vesting through 2027.

What indirect Dexcom (DXCM) holdings are reported for Jacob Leach?

The filing reports 47,296 Dexcom shares held indirectly through the Gregg Family Grandchildren's Trust UAD 12/30/2010. Jacob Leach’s spouse serves as trustee of this trust, and these shares are reported as indirect ownership.

Is the Dexcom (DXCM) CEO’s tax withholding transaction a market sale?

No. The filing states the 19,757 shares were withheld by Dexcom to cover tax withholding and remittance obligations related to RSU net settlement. It explicitly clarifies this does not represent a sale by Jacob Leach.